Structure/function studies on QS-21, a unique immunological adjuvant from Quillaja saponaria

Advances in Experimental Medicine and Biology

Volumn 404, Issue , 1996, Pages 165-172

  Kensil, Charlotte Read ^a   Soltysik, Sean ^a   Wheeler, Deborah A ^a   Wu, Jia Yan ^a  

^a Calypte Biomedical Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOLOGICAL ADJUVANT; QS 21; SAPONIN DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG HYDROLYSIS; DRUG ISOLATION; IMMUNOSTIMULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; T LYMPHOCYTE ACTIVATION;

ANIMALIA; QUILLAJA SAPONARIA; SAPONARIA;

EID: 0030446572     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4899-1367-8_15     Document Type: Conference Paper

References (26)

1. C.R. Kensil, U. Patel, M. Lennick, and D. Marciani, Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex, J. Immunol. 146: 431 (1991).
2. C.R. Kensil, M.J. Newman, R.T. Coughlin, S. Soltysik, D. Bedore, J. Recchia, J.-Y. Wu, and D.J. Marciani, The use of Stimulon adjuvant to boost vaccine response, Vaccine Res. 2: 273 (1993).
3. J. Ma, P.A. Bulger, D.V. Davis, B. Perilli-Palmer, D.A. Bedore, C.R. Kensil, E.M. Young, C.-H. Hung, J.R. Seals, C.S. Pavia, and R.T. Coughlin, Impact of the saponin adjuvant QS-21 and aluminum hydroxide on the immunogenicity of recombinant OspA and OspB of Borrelia burgdorferi, Vaccine 12: 925 (1994).
4. W. Britt, J. Fay, J. Seals, and C. Kensil, Formulation of an immunogenic human cytomegalovirus vaccine: responses in mice, J. Infect. Diseases 171: 18 (1995).
5. R.T. Coughlin, A. Fattom, C. Chu, A.C. White, and S. Winston, Adjuvant activity of QS-21 for experimental E. coli 018 polysaccharide vaccines, Vaccine 13: 17 (1995).
6. J.-Y. Wu, B.H. Gardner, C.I. Murphy, J.R. Seals, C.R. Kensil, J. Recchia, G.A. Beltz, G.W. Newman, and M.J. Newman, Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine, J. Immunol. 148: 1519 (1992).
7. + cytotoxic T lymphocyte responses, J. Immunol. 148: 2357 (1992).
8. G.E. Hancock, D.J. Speelman, P.J. Frenchick, M.M. Mineo-Kuhn, R.B. Baggs, and D.J. Hahn, Formulation of the purified fusion protein of respiratory synctial virus with the saponin QS-21 induces protective immune responses in Balb/c mice that are similar to those generated by experimental infection, Vaccine 13: 391 (1995).
9. P.O. Livingston, S. Adluri, F. Helling, T.-J. Yao, C.R. Kensil, M.J. Newman, and D. Marciani, Phase I trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma, Vaccine 12: 1275 (1994).
10. R. Higuchi and T. Komori, Structures of compounds derived from the acyl moieties of quillajasaponin, Phytochemistry 26: 2357 (1987).
11. 13C-NMR spectroscopy, Carbohydrate Research 280: 1 (1996).
12. J.L. Cleland, C.R. Kensil, A. Lim, N.E. Jacobsen, L. Basa, M. Spellman, D.A. Wheeler, J.-Y. Wu, and M.F. Powell, The isomerization and formulation stability of the vaccine adjuvant QS-21, J. Pharm. Sci. 85: 22 (1996).
13. J.W. Yewdell and J.R. Bennink, The binary logic of antigen processing and presentation to T cells, Cell 62: 203 (1990).
14. + cytotoxic T lymphocytes, J. Exp. Med. 176: 1739 (1992).
15. K. Deres, H. Schild, K. Weismüller, G. Jung, and H. Rammensee, In vivo priming of cytotoxic T lymphocytes with synthetic lipopeptide vaccine, Nature 342: 561 (1989).
16. + cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs, Nature 344: 873 (1990).
17. J. Recchia, M.H.A. Lurantos, J.A. Amsden, J. Storey, and C.R. Kensil, A semisynthetic Quillaja saponin as a drug delivery agent for aminoglycoside antibiotics, Pharm. Res. 12: 1917 (1995).
18. D.J. Pillion, J. Recchia, P. Wang, D.J. Marciani, and C.R. Kensil, DS-1, a modified Quillaja saponin, enhances ocular and nasal absorption of insulin, J. Pharm. Sci. 84: 1276 (1995).
19. M.F. Chaplin , Monosaccharides, in: Carbohydrate Analysis, a Practical Approach, M.F. Chaplin and J.F. Kennedy, eds., IRL Press, Oxford (1986).
20. M.W. Moore, F.R. Carbone, and M.J. Bevan, Introduction of soluble protein into the class I pathway of antigen processing and presentation, Cell 54: 777 (1988).
21. R. Higuchi, Y. Tokimitsu, T. Fujioka, T. Komori, T. Kawasaki, and D.G. Oakenful, Structure of desacylsaponins obtained from the bark of Quillaja saponaria, Phytochemistry 26: 229 (1987).
22. C.R. Kensil, S. Soltysik, U. Patel, and D.J. Marciani, Structure/function relationship in adjuvants from Quillaja saponaria Molina, in: Vaccines 92, F. Brown, R.M. Chanock, H.S. Ginsberg, and R.A. Lerner, eds., Cold Spring Harbor Laboratory Press, Cold Spring Harbor (1992).
23. C.R. Kensil, J.-Y. Wu, and S. Soltysik, Structural and immunological characterization of the vaccine adjuvant QS-21, in: Vaccine Design: The Subunit and Adjuvant Approach, M.F. Powell and M.J. Newman, eds., Plenum Press, New York (1995).
24. R.H. Gisler, G. Schumann, W. Sackmann, C. Pericin, L. Tarcsay, and F.M. Dietrich, A novel muramyl peptide, MTP-PE: profile of biological activities, in: Immunomodulation by Microbial Products and Related Synthetic Compounds, Y. Yamura, S. Kotani, L. Azuma, A. Koda, and T. Shiba, eds., Excerpta Medica, Princeton (1982).
25. R. Hunter, F. Strickland, and F. Kézdy, The adjuvant activity of nonionic block polymer surfactants. I. The role of hydrophile-lipophile balance, J. Immunol. 127: 1244 (1981).
26. S. Soltysik, J.-Y. Wu, J. Recchia, D.A. Wheeler, M.J. Newman, R.T. Coughlin, and C.R. Kensil, Structure/function studies of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function, Vaccine 13: 1403 (1995).